RealFeedApp beta
- Sava Technologies raised 68 million dollars in total funding
London-based Sava Technologies raised $36 million in Series B from Ascensia Diabetes Care to commercialize its subcutaneous glucose sensor. A European launch is scheduled for 18 to 24 months after obtaining CE approval.
- Field
- ageing and longevity
- What they did
- Sava Technologies received a $36 million investment from Ascensia Diabetes Care to accelerate production and clinical trials of its microsensor, which measures blood glucose levels under the skin without finger pricks.
- Why it matters
- This partnership aims to bring the device to the European market and demonstrates strong industry interest in non-invasive glucose monitoring technologies that could replace traditional fingerstick tests.
#glucose sensor#ascensia#medtech#series b#ce approval
